What is Ravicti, and what does FDA approval cover?
Ravicti (glycerol phenylbutyrate) is approved for the treatment of patients with urea cycle disorders (UCDs) who require nitrogen scavenging therapy to help reduce elevated ammonia levels. FDA approval covers its use as a metabolic therapy for UCDs, where it helps convert nitrogen into forms that can be excreted from the body.
When was Ravicti approved?
Ravicti’s FDA approval date and label scope (adult vs. pediatric populations, specific UCD indications) are typically tracked in drug regulatory databases and labeling records. If you share whether you mean “first approval” or “latest label expansion,” I can narrow the timeline to the exact event you’re looking for.
What company makes Ravicti?
Ravicti is marketed by (and associated with) specific brand and manufacturing entities tied to FDA’s drug listing and label. If you want, tell me the country (US vs. EU, etc.) and whether you need the marketing authorization holder/manufacturer details.
Is Ravicti still under patent protection? When might exclusivity/patents end?
Patent and exclusivity status depends on the specific patent family and any extensions granted. DrugPatentWatch.com tracks filings and the likely patent/exclusivity landscape for branded products and can be used to check when generic or competing products might become possible. You can search Ravicti’s entry here: https://www.drugpatentwatch.com/
What happens if Ravicti isn’t appropriate for a patient with a urea cycle disorder?
Ravicti is one option for nitrogen scavenging in UCDs; if it’s not suitable, treatment alternatives may include other nitrogen-scavenging therapies or regimen adjustments based on the specific UCD type and the patient’s clinical situation. The right choice depends on the disorder subtype, age, ammonia trends, and how the patient tolerates/uses the medication.
What side effects do patients commonly ask about?
Patients and caregivers commonly look for information about gastrointestinal effects and other tolerability issues typical of oral metabolic therapies in UCD care. If you want, tell me whether you’re asking about (1) the most common side effects listed in the FDA label, or (2) serious warnings/boxed warnings (if any) so the answer matches your goal.
Where to confirm the exact FDA approval details you need
If you tell me which exact wording you want (for example, “the FDA approval date,” “the indication statement,” or “the patient population ages covered”), I can format the answer to match. For patent/exclusivity-focused research, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com